You are here

VRTX

$147.41

-0.36%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Nov 10, 2017
- In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) ...
Nov 3, 2017
- Data from ongoing extension study of ORKAMBI® (lumacaftor/ivacaftor) in children ages 6-11 and real-world KALYDECO® (ivacaftor) data demonstrate long-term safety and other benefits of these medicines - - New data from ongoing extension study of tezacaftor/ivacaftor combination...
Nov 3, 2017
- Data showed significant improvements in lung function (ppFEV1) with a favorable safety profile across multiple patient groups - - Tezacaftor/ivacaftor currently under review by the FDA and EMA; FDA Priority Review action date of February 28, 2018 - BOSTON--(...
Nov 2, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m. ET. Management's remarks will be available live through Vertex's website at www.v...
Nov 1, 2017
The Vertex Research Innovation Award (RIA) Program Will Now Provide up to $10M in Grants Over the Next Five Years to New Postdoctoral and Faculty Researchers from Around the World BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today a ...
Oct 25, 2017
-Third-quarter 2017 cystic fibrosis product revenues of $550 million, up 34% versus Q3 2016; $336 million for ORKAMBI and $213 million for KALYDECO- -Company increases total 2017 CF product revenue guidance to $2.10 to $2.15 billion; increases ORKAMBI revenue guidance to $1.29 to $1.32 bi...
Oct 23, 2017
Now Accepting Applications for the "All in for CF" Scholarship Program Through Jan. 3, 2018 BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family memb...
Oct 17, 2017
Dedicates $50M to science, technology, engineering, arts and math (STEAM) education for underserved students and establishes The Vertex Foundation Expands global efforts for providing patient and caregiver support including access to our medicines; developing young scientists and physicia...
Oct 16, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 50...
Sep 21, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.m. ET Management's remarks will be avail...
Sep 19, 2017
-Eleven abstracts from Vertex's CF program accepted for presentation- -Late-breaking abstract submitted with data from three different triple combination regimens in CF patients- BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today annou...
Sep 7, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Monday, September 11, 2017 at 1:40 p.m. ET. Management's remarks will be available live through Vertex's website at www....
Sep 6, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO). Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice President and Chief ...
Aug 24, 2017
-FDA grants Priority Review of the application and sets action date of February 28, 2018- -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function ...
Aug 1, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who have one of five residual function mutations...
Page:
...
Next Last